Oncolytic Viruses for Cancer Immunotherapy

Oncolytic Viruses for Cancer Immunotherapy: Review

Oncolytic virus immunotherapy is a therapeutic approach to cancer treatment that utilizes native or genetically modified viruses that selectively replicate within tumour cells.
Oncolytic viruses represent a new class of therapeutic agents that promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity.
There are numerous oncolytic viruses in clinical development for cancer immunotherapy: Herpes simplex viruses, Adenoviruses, Vaccinia virus, Coxsackievirus, Newcastle disease virus, Measles virus, Poliovirus……
A recent randomized Phase III clinical trial demonstrated an improved durable response rate for patients with advanced melanoma who were treated with a modified herpes simplex virus type 1 (HSV-1), encoding granulocyte–macrophage colony-stimulating factor (GM-CSF). This virus, termed talimogene laherparepvec (T-VEC; Amgen), is widely anticipated to be the first oncolytic virus immunotherapy to be approved by the US Food and Drug Administration (FDA) for the treatment of cancer. The success of T-VEC is likely to promote further drug development within this new class of cancer therapeutics.
Oncolytic virus immunotherapy is a highly promising approach and introduces a new class of drugs for treating patients with cancer.

Oncolytic Viruses for Cancer Immunotherapy: Review

Kaufman H L et al. Oncolytic viruses: a new class of immunotherapy drugs[J]. Nature Reviews Drug Discovery, 2015, 14(9): 642-662.
Andtbacka R H I et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. Journal of Clinical Oncology, 2015: JCO. 2014.58. 3377.

Immunotherapy
What is Immunotherapy
Cancer Immunotherapy
What is Immunotherapy for Cancer
Monoclonal Antibody for Cancer Immunotherapy
Immune Checkpoint
Vaccines for Cancer Immunotherapy
Immune Modulation for Cancer Immunotherapy
Oncolytic Viruses for Cancer Immunotherapy
Adoptive Immunotherapy for Cancer+
- What is Adoptive Immunotherapy for Cancer
- Tumor-Infiltrating Lymphocytes (TILs) for Cancer Immunotherapy
- Chimeric Antigen Receptor (CAR) T-cell for Cancer Immunotherapy
- Epstein–Barr Virus (EBV)-Specific T Cells for Cancer Immunotherapy
Immunotherapy for Lung Cancer
Immunotherapy for Melanoma
Cancer Immunotherapy for Breast Cancer
Immunotherapy for Prostate Cancer
Immunotherapy for Pancreatic Cancer
Immunotherapy for Ovavian Cancer
Immunotherapy for Colon Cancer
Immunotherapy for Bladder Cancer
Immunotherapy for Liver Cancer
Immunotherapy for Kidney Cancer
Immunotherapy for Brain Cancer
Immunotherapy for Esophageal Cancer
Immunotherapy for Gastric Cancer
Cancer Immunotherapy for Leukemia
Cancer Immunotherapy Clinical Trials
Cancer Immunotherapy Companies
Immunotherapy Drugs for Cancer
Breakthrough of Cancer Immunotherapy
Side Effects of Immunotherapy for Cancer
Cancer Immuotherapy Conference
Cancer Immuotherapy Related Molecules+
- Immune Checkpoint Targets
- Monoclonal Antibody Targets for Cancer Immunotherapy
- Vaccine Antigens for Cancer Immunotherapy
- Cytokines for Cancer Immunotherapy
- Tumor Antigens for Cancer Immunotherapy
Allergy Immunotherapy
Autoimmune Diseases Immunotherapy
Immunotherapy Related Molecules
Sublingual Immunotherapy
Side Effects of Immunotherapy
Immunotherapy Drugs
Adoptive Immunotherapy
Journal of Immunotherapy
Immunotherapy Conference